Keryx Biopharmaceuticals (KERX) Soars On Baupost Deal

Rupert Hargreaves

Published onOctober 15, 2015

Updated on May 13, 2021

Baupost Group, the hedge fund managed by acclaimed value investor Seth Klarman, has once again boosted its holding in Keryx Biopharmaceuticals.

[klarman]

[dalio]

Today, Keryx announced that it has entered into an agreement with funds managed by Baupost Group, L.L.C, to raise $125 million through the private placement of Convertible Senior Notes, due 2020.

Via S&P CapIQ Keryx Biopharmaceuticals KERX Soars On Baupost deal — Via S&P CapIQ

[drizzle]

Keryx Biopharmaceuticals is focused on bringing innovative therapies to market for people with renal disease. Baupost has held a position in the company since May 2014.

And Klarman has been steadily increasing his position in Keryx since the second quarter of last year. After...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Rupert Hargreaves

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for Hedge Fund Alpha

Keryx Biopharmaceuticals (KERX) Soars On Baupost Deal

Login required to continue reading.

Get Your Business News